An Open-Label, Long-term (52-week), Safety Trial of the Fixed Dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 12.5mg and Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg in Patients With Essential Hypertension - Efficacy and Safety Evaluation.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Telmisartan/hydrochlorothiazide (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 17 Jan 2007 Status change
- 13 Nov 2006 New trial record.